Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implementing a performance-based MEA at the hospi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Panos Kefalas, Omar Ali, Jesper Jørgensen, Nick Merryfield, Tim Richardson, Adam Meads, Laura Mungapen, Matthew Durdy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2018-01-01
coleção:	Journal of Market Access & Health Policy
Assuntos:	Value-based agreements managed entry agreement patient access scheme reimbursement Chimeric Antigen Receptor T-cell therapy acute lymphoblastic leukaemia regenerative medicine outcomes-based innovative contracting
Acesso em linha:	http://dx.doi.org/10.1080/20016689.2018.1511679
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!